Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy

Gut

Volumn 46, Issue 5, 2000, Pages 615-621

  Schenk, B E ^a   Kuipers, E J ^a   Klinkenberg Knol, E C ^a   Meuwissen, S G M ^a   Nelis, G F ^b   Thijs, J C ^c   Snel, P ^d   Luckers, A E G ^e   Festen, H P M ^f   Viergever, P P ^g   Bloemena, E ^a   Lindeman, J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Sophia Hospital   (Netherlands)

^c Bethesda Hospital   (Netherlands)

^d SLOTERVAART HOSPITAL   (Netherlands)

^e Maas Hospital Pantein   (Netherlands)

^f Groot Ziekengasthuis Den Bosch ^*  (Netherlands)

^g Location Alkmaar   (Netherlands)

Author keywords

Atropy; Gastritis; Gastro oesophageal reflux disease; Helicobacter pylori; Omeprazole

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CLARITHROMYCIN; OMEPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR;

ARTICLE; ATROPHIC GASTRITIS; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; GASTRITIS; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HISTOLOGY; HUMAN; HUMAN TISSUE; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; TREATMENT OUTCOME;

ADULT; AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; CASE-CONTROL STUDIES; CLARITHROMYCIN; ESOPHAGITIS, PEPTIC; FEMALE; GASTRITIS, ATROPHIC; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PENICILLINS; PROSPECTIVE STUDIES;

EID: 0034065646     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.46.5.615     Document Type: Article

References (35)

1. 1 Marshall BJ, Armstrong JA, McGechie DB, et al. Attempt to fulfil Koch's postulates for pyloric Campylobacter. Med J Austr 1985;142:436-9.
2. 2 Morris A, Nicholson G. Ingestion of Campylobacter pyloridis causes gastritis and raised fasting gastric pH. Am J Gastroenterol 1987;82:192-9.
3. 3 Dixon MF. Helicobacter pylori and peptic ulceration; histopathological aspects. J Gastroenterol Hepatol 1991;6: 125-30.
4. 4 Rauws EAJ, Langenberg W, Houthoff HJ, et al. Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and anti-ulcer treatment. Gastroenterology 1988;94:33-40.
5. 5 Sipponen P. Long-term consequences of gastroduodenal inflammation. Eur J Gastroenterol Hepatol 1992;4 (suppl 2):S25-9.
6. 6 Kuipers EJ, Uyterlinde AM, Peña AS, et al. Long term sequelae of Helicobacter pylori gastritis. Lancet 1995;345: 1525-8.
7. 7 Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991;325:1127-31.
8. 8 IARC monographs on the evaluation of carcinogenic risks to humans, vol 61, schistosomes, liver flukes and Helicobacter pylori. Lyon: International Agency for Research on Cancer, 1994.
9. 9 Miehlke S, Hackelsberger A, Meining A, et al. Histological diagnosis of Helicobacter pylori gastritis is predictive of a high risk of gastric carcinoma. Int J Cancer 1997;73:837-9.
10. 10 Logan RPH, Walker MM, Misiewicz JJ, et al. Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut 1995;36:12-16.
11. 11 Sachs G. Gastritis, Helicobacter pylori, and proton pump inhibitors. Gastroenterology 1997;112:1033-6.
12. 12 Kuipers EJ, Lee A, Klinkenberg-Knol EC, Meuwissen SGM. Review article: The development of atrophic gastritis - Helicobacter pylori and the effects of acid suppressive therapy. Aliment Pharmacol Ther 1995;9:331-40.
13. 13 Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux oesophagitis treated with omeprazole or fundoplication. N Engl J Med 1996;334:1018-22.
14. 14 Kolkman JJ, Hazenberg HJA, Dekker N, et al. The effect of acid suppression on H. pylori gastritis is dose dependant. Gastroenterology 1998;112:A128.
15. 15 Lamberts R, Creutzfeldt W, Strüber HG, et al. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology 1993; 104:1356-70.
16. 16 Eissele R, Brunner G, Simon B, et al. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil-cell hyperplasia. Gastroenterology 1997; 112:707-17.
17. 17 Berstad AE, Hatlebakk JG, Maartmann-Moe H, et al. Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole. Gut 1997;41:740-7.
18. 18 Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis. The updated Sydney system. Am J Surg Pathol 1996;20:1161-81.
19. 19 Sipponen P, Kekki M, Haapakoski J, et al. Gastric cancer risk in chronic atrophic gastritis: statistical calculations of cross-sectional data. Int J Cancer 1985;35:173-7.
20. 20 Correa P. Human gastric carcinogenesis: a multistep and multifactorial process. Cancer Res 1992;52:6735-40.
21. 21 Kuipers EJ, Pérez-Pérez GI, Meuwissen SGM, et al. Helicobacter pylori and atrophic gastritis; importance of the cagA status. J Natl Cancer Inst 1995;87:1777-80.
22. 22 Blaser MJ, Pèrez-Pérez GI, Kleanthous H, et al. Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res 1995;55:2111-15.
23. 23 Kuipers EJ, Uyterlinde AM, Peña AS, et al. Increase of Helicobacter pylori associated corpus gastritis during acid suppressive therapy: Implications for long-term safety. Am J Gastroenterol 1995;90:1401-6.
24. 24 Stolte M, Meining A, Schmitz JM, et al. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1998;12:247-53.
25. 25 Meining A, Bossecker H, Caspary WF, et al. H2-receptor antagonists and antacids have an aggravating effect on Helicobacter pylori gastritis in duodenal ulcer patients. Aliment Pharmacol Ther 1997;11:729-34.
26. 26 Lundell L, Miettinen P, Myrvold HE, et al. Lack of effect of acid suppressive therapy on gastric atrophy. Gastroenterology 1999;117:319-26.
27. 27 Genta RM. Acid suppression and gastric atrophy: sifting fact from fiction. Gut 1998;43 (suppl 1):S35-8.
28. 12 levels. Aliment Pharmacol Ther 1999;13:1343-6.
29. 29 Grieken van NCT, Weiss MM, Meyer GA, et al. Rapid quantitative assessment of gastric corpus atrophy in tissue sections. Gastroenterology 1999;4:A177.
30. 30 Sachs, G. Gastritis, Helicobacter pylori, and proton pump inhibitors. Gastroenterology 1997;112:1033-6.
31. 31 Stolte M, Baumann K, Bethke B, et al. Active autoimmune gastritis without total atrophy of the glands. Z Gastroenterol 1992;30:729-35.
32. 32 Lind T, Veldhuysen van Zanten S, Unge P, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole and two antimicrobials: The MACH 1 study. Helicobacter 1996;1:138-44.
33. 33 Athmann C, Mander I, Brunner G, et al. Histology and safety parameters during long-term maintenance with pantozole in severe acid-peptic disease. Gastroenterology 1998;114:A60.
34. 34 Meining AG, Bayerdorffer E, Stolte M. Helicobacter pylori gastritis of the gastric cancer phenotype in relatives of gastric carcinoma patients. Eur J Gastroenterol Hepatol 1999;11:717-20.
35. 35 Moayyedi P, Morrow S, Peacock R, et al. Changing patterns of H. pylori gastritis in long-standing acid suppression. Gastroenterology 1999;116:A257.